Pilot Study in Patients With Symptomatic Steroid-Naive Asthma
NCT ID: NCT00024544
Last Updated: 2012-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
120 participants
INTERVENTIONAL
2001-08-31
2003-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Daclizumab in Patients With Chronic, Persistent Asthma
NCT00028288
The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563)
NCT00292877
Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
NCT02334553
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
NCT01591044
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
NCT00870584
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
anti-IL-4 monoclonal antibody (pascolizumab)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No use of inhaled, oral or injectable steroids for at least 1 month prior to enrollment
Exclusion Criteria
* No significant disease other than asthma
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Facet Biotech
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Allergy Research Foundation
Los Angeles, California, United States
Southern California Research
Mission Viejo, California, United States
Clinical Trials of Orange Cnty., Inc.
Orange, California, United States
Allergy Associates Medical Group, Inc.
San Diego, California, United States
Allergy and Asthma Associates Santa Clara Valley Research Center
San Jose, California, United States
Bensch Research Associates
Stockton, California, United States
National Jewish Medical and Research Center
Denver, Colorado, United States
ICSL Clinical Studies
Normal, Illinois, United States
Respiratory Therapy and Pulmonary Clinical Research Brigham & Women's Hospital
Boston, Massachusetts, United States
New England Clinical Studies
North Dartmouth, Massachusetts, United States
Clinical Research Institute
Minneapolis, Minnesota, United States
The Clinical Research Center, LLC
St Louis, Missouri, United States
Center for Allergy, Asthma and Immunology, Creighton University
Omaha, Nebraska, United States
Princeton Center for Clinical Research
Princeton, New Jersey, United States
Allergy, Asthma, and Dermatology Research Center, LLC
Lake Oswego, Oregon, United States
Valley Clinical Research Center
Easton, Pennsylvania, United States
Clinical Trials North Houston
Houston, Texas, United States
University of Wisconsin Medical School
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
683-803
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.